{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
histamine
to a specific field?
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Status:
Investigational
Source:
NCT01772199: Phase 2 Interventional Completed Multiple Sclerosis, Relapsing-Remitting
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
GlaxoSmithKline (GSK) was developing GSK-239512 as a histamine H3 receptor antagonist/inverse agonist as a monotherapy treatment for subjects with mild-to-moderate probable Alzheimer's disease (AD), multiple sclerosis and Schizophrenia. However, in March 2017, GSK globally discontinued the study of GSK-239512 at phase II.
Status:
Investigational
Source:
INN:methiomeprazine [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT04711915: Phase 1 Interventional Active, not recruiting Major Depressive Disorder
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Status:
Investigational
Source:
NCT01093508: Phase 1 Interventional Completed Narcolepsy With or Without Cataplexy
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ACHIRAL)
Nemazoline (A-57219) is a nasal decongestant. It has alpha 1-agonist/alpha 2-antagonist activity and was more effective and long-acting than oxymetazoline on canine nasal mucosa, in-vitro and in-vivo. Upon intranasal administration to dogs, the compound was devoid of systemic effects up to a concentration 1000 times that needed for local decongestant effect (1.65 micrograms, atomized from a 1 microgram mL-1 solution) suggesting limited mucosal absorption. After nasal administration to rats for 15 days at a concentration 1000 times greater than that required for nasal decongestion, no mucosal tissue toxicity or systemic effects were seen.
Class (Stereo):
CHEMICAL (ACHIRAL)
Fuprazole was developed as a bronchodilator that has never been marketed. Information about the current use of this compound is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Tagorizine (also known as AL-3264) is a pyridylacrylamidoalkylpiperazine derivative patented by Dainippon Pharmaceutical Co., Ltd as an antiallergic agent. Tagorizine acts as 5-lipoxygenase inhibitor and blocks histamine H1-receptors in isolated guinea pig trachea, inhibits antigen-induced histamine release from isolated rat peritoneal mast cells, and suppress leukotriene production from activated human leukocytes. In preclinical models Tagorizine inhibited the antigen-induced leukotriene production in the abdominal cavity of passively sensitized rats and suppressed the arachidonic acid-induced ear edema in mice.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Dimelazine is a sedative, antihistaminic agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Decloxizine (UCB-1402; NSC289116) is a histamine 1 receptor antagonist. Decloxizine is a broncholyticum.
